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ABSTRACT
Understanding the aspects of the cell functionality that account for disease 
or drug action mechanisms is a main challenge for precision medicine. Here we 
propose a new method that models cell signaling using biological knowledge 
on signal transduction. The method recodes individual gene expression values 
(and/or gene mutations) into accurate measurements of changes in the activity 
of signaling circuits, which ultimately constitute high-throughput estimations of 
cell functionalities caused by gene activity within the pathway. Moreover, such 
estimations can be obtained either at cohort-level, in case/control comparisons, or 
personalized for individual patients. The accuracy of the method is demonstrated 
in an extensive analysis involving 5640 patients from 12 different cancer types. 
Circuit activity measurements not only have a high diagnostic value but also can be 
related to relevant disease outcomes such as survival, and can be used to assess 
therapeutic interventions.
INTRODUCTION
Despite most phenotypic traits (including disease 
and drug response) are multi-genic, the vast majority of 
biomarkers in use are based on unique gene alterations 
(expression changes, mutations, etc.) Obviously, the 
determination of the status of a single gene is technically 
easier than multiple gene measurements. However, 
regardless of their extensive clinical utility, single gene 
biomarkers frequently lack any mechanistic link to the 
fundamental cellular processes responsible for disease 
progression or therapeutic response. Such processes are 
better understood as pathological alterations in the normal 
operation of functional modules caused by different 
combinations of gene perturbations (mutations or gene 
expression changes) rather than by alterations of a unique 
gene [1].
Of particular interest are signaling pathways, a 
type of functional module known to play a key role in 
cancer origin and progression, as well as in other diseases. 
Consequently, analysis of the activity of signaling 
pathways should provide a more informative insight 
of cellular function. Actually, the recent demonstration 
that the inferred activity of the c-Jun N-terminal kinase 
pathway, shows significantly higher association to 
neuroblastoma patients’ mortality than the activity of 
their constituent genes (including MICN, the conventional 
neuroblastoma biomarker) [2] constitutes an elegant 
confirmation of this concept. In a similar example 
drug sensitivity is shown to be better predicted using 
probabilistic signaling pathway models than directly using 
gene activity values [3].
However, conventional methods for pathway 
analysis, even the most sophisticated ones based on 
pathway topology, can only detect the existence of a 
significant level of gene activity within the pathway [4]. 
However, these methods ignore the obvious fact that many 
pathways are multifunctional and often trigger opposite 
functions (e.g. depending the receptor and the effector 
proteins involved in the transduction of the signal, the 
apoptosis pathway may trigger survival or cell death). 
Moreover, whether the level of gene activity detected by 
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conventional methods actually triggers cell functionalities 
or not and, if so, what genes are the ultimate responsible 
for the resulting cell activity is something that must be 
determined a posteriori, usually by heuristic methods. 
Thus, pathway activity analysis (PAA) emerges as an 
alternative way of defining a new class of mechanistic 
biomarkers, whose activity is related to the molecular 
mechanisms that account for disease progression or drug 
response. However, capturing the aspects of the activity of 
the pathway that are really related to cell functionality is 
not trivial. This requires of an appropriate description of 
the elementary sub-pathways and an adequate computation 
of the individual contributions of gene activities to 
the actual activity of the sub-pathway. Different ways 
of computing activity scores for diverse sub-pathway 
definitions using gene expression values [5–8], or even 
gene mutations [9], have been proposed (See Table 1). 
However, in most of them sub-pathway definition is either 
disconnected, or only collaterally related, to the functional 
consequences of pathway activity (See Table 1).
Here we propose a new method to estimate the 
activity within a pathway that uses biological knowledge 
on cell signaling to recode individual gene expression 
values (and/or gene mutations) into measurements that 
ultimately account for cell functionalities caused by the 
activity of the pathway. Specifically, we estimate the level 
of activity of stimulus-response sub-pathways (signaling 
circuits thereinafter) within signaling pathways, which 
ultimately trigger cell responses (e.g. proliferation, 
cell death, etc.) The activity values of these canonical 
circuits connected to the activation/deactivation of cell 
functionalities can be considered multigenic mechanistic 
biomarkers that can easily be related to phenotypes and 
provide direct clues to understand disease mechanisms 
and drug mechanisms of action (MoA). Therefore, we 
designate this method as canonical circuit activity analysis 
(CCAA).
RESULTS
Data pre-processing
RNA-seq counts for 12 cancer types listed in Table 
2 were downloaded from The Cancer Genome Atlas 
(TCGA) data portal (https://tcga-data.nci.nih.gov/tcga/). In 
order to detect possible batch effects, principal component 
analysis (PCA) were calculated. The samples were plotted 
in the PCA representation by sequencing center, plate, 
cancer type and project. Only a clear batch effect by 
sequencing center and cancer was found (Figure S1A to 
S1E, upper panel), that was corrected by the application 
of the COMBAT [10] method (Figure S1F to S1J, lower 
panels). Then, the 538 samples of the Kidney renal clear 
cell carcinoma (KIRC) dataset were further normalized 
using TMM [11] to account for RNA composition bias. 
Normalized data were used as input for the CCAA method.
Estimation of the specificity of the CCAA 
method
In order to estimate the false positive rate, we 
generated different sets of indistinguishable samples 
that were randomly divided into two groups which were 
compared to try to find differentially activated circuits. 
Given that the compared groups are composed of the 
same type of individuals, any significant difference in 
sub-pathway activity found in the comparisons would 
be considered a false positive of the method. Real and 
simulated samples were used for this purpose (see 
Methods) and the ratio of false positives was always very 
low, far below the conventional alpha value of 0.05 (see 
Figure S2).
Estimation of the sensitivity of the CCAA 
method
In order to obtain an estimation the true positive rate 
of the CCAA method, we compared cancer samples versus 
the corresponding healthy tissue in a series of contrasts 
with different sizes (N=50,100,200 and 400 samples; see 
Methods) from which we expect differences in cancer-
associated pathways. Two different cancer types, KIRC 
and BRCA, were used to avoid biases derived from 
using only a specific type of cancer. We have used two 
definitions of cancer associated pathways, one of them 
taken from KEGG (composed of 14 pathways belonging to 
the Cancer pathways category, see Table 3), and the other 
one that contains 49 pathways curated by experts (Table 
4). Figure S3 shows how, except in the case of very small 
datasets in which the statistical power of the method for 
detecting significant differences is limited, the proposed 
CCAA methodology clearly identifies significant changes 
for both cancers in the two cancer pathway definitions 
used.
Comparison to other available PAA methods
The performance of our method was compared to 
other PAA methods that provide different definitions of 
sub-pathways and distinct algorithms to calculate a score 
for them. From the list in (Table 1) we used eight methods 
that satisfy two basic conditions: they can be applied to 
RNA-seq data and there is software available for running 
them. These are: DEAP [12], subSPIA [13], using their 
own software, and topologyGSA [14], DEGraph [6], 
clipper [5], TAPPA [15], PRS [16], PWEA [17], using 
the implementation available in the topaseq package [18]. 
Figure 1 represents the true positive and true negative 
ratios obtained for any of the methods compared (See 
Methods). While most of the pathway activity definitions 
are reasonably specific, with true negative ratios over 
95% (except clipper, topologyGSA and PWEA, probably 
because they define sub-pathways unconnected with 
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Table 1: List of methods for Pathway Analysis
Method Date Code Pathway modelled Entity modelled Input Output Comparison Loops
MinePath[52] 2015
Web application
http://minepath.
org/
KEGG pathways
Subpath 
identification
MA
p-value per 
pathway
p-value per 
subpathway
binary value per 
sample
graphical 
visualization
Two 
conditions NA
Qin et al.[53] 2015 NA 12 cancer-related 
KEGG pathways
signal 
quantification
Mutations
CNVs
Cancer 
drugs
Pathway 
activity Personalized yes
subSPIA[13] 2015 R code KEGG pathways signal 
quantification
MA
RNAseq 
(via 
SPIA in 
ToPASeq)
p-value of DE 
per subpathway
p-value of PF 
per subpathway
global p-value 
(DE+PF)
Two 
conditions no
Pathome[54] 2014 NA KEGG pathways signal 
quantification
MA
RNAseq
p-value per 
subpathway
Two 
conditions NA
Pepe et al.[55] 2014 R code KEGG pathways subpath 
identification
MA p-value per subpathway
Two 
conditions NA
ToPaSeq[18] 2014 R package
graphite gene-gene 
networks
user's pathways
integrates other 
methods:
TopologyGSA
DEGraph
Clipper
SPIA
TAPPA
PRS
PWEA
MA
RNAseq
Depends on the 
method
Two 
conditions
Depends 
on the 
method
DEAP[12] 2013 python code user defined pathway structure
signal 
quantification
MA
RNAseq
Score and 
p-value per 
pathway
subgraph with 
the maximum 
absolute score
Two 
conditions yes
CliPPER[5] 2013
R package
ToPASeq R 
package
graphite gene-gene 
networks
cliques
user's pathways 
(via ToPASeq)
subpath 
identification
MA
RNAseq
p-value at 
pathway level
Most affected 
subgraph per 
pathway
Gene-level 
statistics for DE 
of genes
Two 
conditions no
GraphiteWeb[56] 2013
Web application:
http://graphiteweb.
bio.unipd.it/R 
package
KEGG pathways
Reactome 
pathways
integrates other 
methods:
Hypergeometric 
test
Global Test
GSEA
SPIA
CliPPER
MA
RNAseq
Significant 
pathways
Visualization 
of the pathways 
with nodes 
coloured 
according 
to their 
contribution to 
the analysis
Two 
conditions no
TEAK[57] 2013
Code @ Google 
(Windows and 
Mac)
KEGG  
pathways
metabolism-
orientedsubpathway 
identification
MA Ranked subpathways
Two 
conditions no
 (Continued )
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Method Date Code Pathway modelled Entity modelled Input Output Comparison Loops
PRS[16] 2012 ToPASeq R package
graphite gene-
gene networks 
(ToPASeq)
user's pathways 
(via ToPASeq)
pathway 
identification
MA
RNAseq
p-value per 
pathway
gene-level 
statistics for DE 
of genes
Two 
conditions yes
DEGraph[6] 2012
R 
packageToPASeq 
R package
subgraphs of 
a large graph 
(branch-and-
bound-like 
approach) 
graphite gene-
gene networks 
(ToPASeq)
user's pathways 
(via ToPASeq)
subpath 
identification
MA
RNAseq
p-value of DE 
per subpathway
p-value per 
pathway
Gene-level 
statistics for DE 
of genes
Two 
conditions no
Rivera et al.[58] 2012 NA NetPathpathways subpath 
identification
MA
p-value of 
most perturbed 
subpathway
Two 
conditions NA
Chen et al.[59] 2011 NA KEGG pathways subpath 
identification
MA
p-value per 
subpathway
p-value of key 
genes
Two 
conditions NA
PWEA[17] 2010 ToPASeq R package
Complete 
pathways (KEGG)
graphite gene-
gene networks 
(ToPASeq)
user's pathways 
(via ToPASeq)
pathway 
identification
MA
RNAseq
p-value of DE 
per pathway
Gene-level 
statistics for DE 
of genes
Two 
conditions no
TopologyGSA[14] 2010 ToPASeq R package
Complete 
pathways (KEGG)
Cliques
graphite gene-
gene networks 
(ToPASeq)
user's pathways 
(via ToPASeq)
subpath 
identification
MA
RNAseq
p-value of DE 
per pathway
Gene-level 
statistics for DE 
of genes
Two 
conditions no
DEGAS[60] 2010 Java (Windows) KEGG pathways
PPIs network
novel subpath 
identification
MA A subpathway per pathway
Two 
conditions NA
TAPPA[15] 2007
ToPASeq R 
package
graphite gene-
gene networks 
(ToPASeq)
user's pathways 
(via ToPASeq)
pathway 
identification
MA
RNASeq
p-value of DE 
per pathway
Gene-level 
statistics for DE 
of genes
Two 
conditions no
The first column (Method) contains the name or acronym of the method, if exists, otherwise, we refer to it as the fires author of 
the publication. The second column (Date) contains the publication date. The third column (code) informs on the availability of 
the code to run the method. The fourth column (Pathway modelled) indicates the pathway definition used in the method. The fifth 
column (Entity modelled) is the entity, within the pathway, used in the method (“subpath identification” methods obtain candidate 
sub-pathways usually by differential expression of its constituent genes, “signal quantification” methods provide, in addition, a 
quantification of the activation status of the sub-pathway). The sixth column (input) indicates the data type that inputs the method 
(MA: Expression Microarray; CNV: copy number variation; NA: not available). The seventh column (output) describes the results 
provided by the method. Some provide only a score (p-value, DE: differential expression matrix; PF: perturbation factor) for the 
whole pathway and other also provide scores for sub-pathways, that can be defined within the pathways in many different ways. 
The eight column (Comparison) indicates the type of comparison the method can deal with. It can be either a conventional two 
conditions (typically case/control) comparison or it can allow obtaining personalized results per individual. And the ninth column 
(Loops) indicates whether the method can handle loop structures in the topology of the sub-pathway analysed or not.
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cell functionality), the sensitivity is generally low (in 
most cases below 50%). When the curated list of cancer 
pathways (see Table 4) is used, the performance of some 
methods improves but still, the sensibility is in general low 
(clearly below 75%, see Figure S4).
From the technical standpoint, the CCAA method 
can handle loops in the pathway topology, a feature absent 
in most PAA methods (see Table 1) allowing a more 
comprehensive description of the circuit activity.
These results demonstrates that all the PAA methods 
analyzed, except ours, are not properly capturing the 
biological signal and consequently failed to detect cancer 
pathway activities when cancer and normal tissues were 
compared, across twelve different cancer types.
A case example with kidney renal clear cell 
carcinoma
To demonstrate the utility of this approach in defining 
the activity of canonical signaling circuits as highly 
reliable mechanistic biomarkers that, in addition, account 
for important disease outcomes such as survival, kidney 
renal clear cell carcinoma (KIRC) [19] data was used. In 
addition, survival data available on patients were used to 
Table 3: KEGG cancer pathways
KEGG identifier Name
hsa04010 MAPK signaling pathway
hsa04310 Wnt signaling pathway
hsa04350 TGF-beta signaling pathway
hsa04370 VEGF signaling pathway
hsa04630 Jak-STAT signaling pathway
hsa04024 cAMP signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04150 mTOR signaling pathway
hsa04110 Cell cycle
hsa04210 Apoptosis
hsa04115 p53 signaling pathway
hsa04510 Focal adhesion
hsa04520 Adherens junction
hsa03320 PPAR signaling pathway
Table 2: Cancers used in this study with the number of samples sequenced of both tumour biopsy and normal 
adjacent tissue
TCGA 
Identifier
Cancer Primary tumor Normal adjacent tissue Ref.
BLCA Bladder Urothelial Carcinoma 301 17 [29]
BRCA Breast invasive carcinoma 1057 113 [30]
COAD Colon adenocarcinoma 451 41 [31]
HNSC Head and Neck squamous cell carcinoma 480 42 [32]
KIRC Kidney renal clear cell carcinoma 526 72 [19]
KIRP
Kidney renal papillary cell 
carcinoma 222 32 [33]
LIHC Liver hepatocellular carcinoma 294 48 -
LUAD Lung adenocarcinoma 486 55 [34]
LUSC Lung squamous cell carcinoma 428 45 [35]
PRAD Prostate adenocarcinoma 379 52 [36]
THCA Thyroid carcinoma 500 58 [37]
UCEC Uterine Corpus Endometrial Carcinoma 516 23 [38]
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Table 4: Curated cancer pathways
KEGG identifier Name
hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04010 MAPK signaling pathway
hsa04012 ErbB signaling pathway
hsa04310 Wnt signaling pathway
hsa04330 Notch signaling pathway
hsa04340 Hedgehog signaling pathway
hsa04350 TGF-beta signaling pathway
hsa04390 Hippo signaling pathway
hsa04370 VEGF signaling pathway
hsa04630 Jak-STAT signaling pathway
hsa04064 NF-kappa B signaling pathway
hsa04668 TNF signaling pathway
hsa04066 HIF-1 signaling pathway
hsa04068 FoxO signaling pathway
hsa04020 Calcium signaling pathway
hsa04024 cAMP signaling pathway
hsa04022 cGMP-PKG signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04152 AMPK signaling pathway
hsa04150 mTOR signaling pathway
hsa04110 Cell cycle
hsa04114 Oocyte meiosis
hsa04210 Apoptosis
hsa04115 p53 signaling pathway
hsa04510 Focal adhesion
hsa04520 Adherens junction
hsa04530 Tight junction
hsa04540 Gap junction
hsa04611 Platelet activation
hsa04620 Toll-like receptor signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04650 Natural killer cell mediated cytotoxicity
hsa04660 T cell receptor signaling pathway
hsa04662 B cell receptor signaling pathway
hsa04670 Leukocyte transendothelial migration
hsa04062 Chemokine signaling pathway
 (Continued )
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KEGG identifier Name
hsa04910 Insulin signaling pathway
hsa04920 Adipocytokine signaling pathway
hsa03320 PPAR signaling pathway
hsa04912 GnRH signaling pathway
hsa04915 Estrogen signaling pathway
hsa04914 Progesterone-mediated oocyte maturation
hsa04919 Thyroid hormone signaling pathway
hsa04916 Melanogenesis
hsa05200 Pathways in cancer
hsa05231 Choline metabolism in cancer
hsa05202 Transcriptional misregulation in cancer
hsa05205 Proteoglycans in cancer
demonstrate that the activity of many of the selected circuits 
is significantly related to the prognostic of the disease.
Firstly, 526 cancer samples were compared against the 
72 available controls of normal kidney tissue adjacent to the 
primary tumors (See Table 2). The comparison was made at 
the level of canonical circuits (see Methods), effector circuits 
and functions (using both Uniprot and GO annotations). As 
expectable, given the large number of differentially expressed 
genes between the cancer and the healthy tissue [19], a large 
number of signaling circuits present a significant differential 
activation between the compared conditions (4966 with 
a FDR-adjusted p-value < 0.01; See Table S1). Focusing 
on effector circuits, this signaling interplay is reduced to 
870 significant changes in the intensity of signal reception 
(with a FDR-adjusted p-value < 0.01; See Table S2). These 
effector nodes significantly trigger 71 cell functionalities 
(according to Uniprot general definitions, see Table S3, 
which summarize 320 more detailed cell functionalities 
according to GO definitions, see Table S4; both with a FDR-
adjusted p-value < 0.01). Figure 2 summarizes the different 
functions dysregulated by circuits in different KEGG cancer 
pathways (see Table 3) and the corresponding impact on 
patient’s survival. Figure S5 expands this summary to the 
set of curated cancer pathways listed in Table 4. Although 
some functionalities are quite general descriptions of cellular 
biological processes and others can be consequences of the 
extreme deregulation process occurring in cancer cells, 
a considerable number of them can be clearly linked to 
tumorigenic processes and can easily be mapped to cancer 
hallmarks [20].
Circuits that trigger cancer hallmarks determine 
patient survival
Since survival data was among the clinical 
information available survival analysis of the significant 
effector circuits, and functions listed in Tables S1, S2, 
S3 and S4) was carried out. This analysis provides an 
independent validation of the involvement of several cell 
functionalities, as well as several signaling circuits that 
trigger them, in cancer pathogenesis.
Survival analysis discovered a total of 310 effector 
circuits whose dysregulation is significantly associated to 
good or poor cancer prognostic (Table S5). These circuits 
trigger a total of 31 general cell functionalities, according 
to Uniprot definitions (Table S6) that can be expanded to 
108 more detailed GO definitions (Table S7), which are 
significantly related to patient’s survival.
The main cancer hallmark is sustained proliferation 
[20]. A clear example of effector circuit related to this 
hallmark is the CCNA2, from the AMPK signaling 
pathway, whose high levels of activity are significantly 
associated to bad prognostic in the patients in which 
triggers the Cell division function (Figure S6A). Actually, 
there is a significant increase in the activity of the CCNA2 
effector circuit as cancer stage progresses (Figure S6C). 
In fact, dysregulated genes were recently identified in this 
sub-pathway that might be potential biological markers 
and processes for treatment and etiology mechanism 
in KIRC [21]. Another similar example is the effector 
circuit ending in node CDK2, CCNE1 from the p53 
signaling pathway, and triggering the Cell cycle function, 
whose increased activity is significantly associated to 
bad prognostic in KIRC patients (Figure S7A and S7B). 
In addition, there is a significant increase in the activity 
of the CDK2, CCNE1 effector circuit as cancer stage 
progresses (Figure S7C). Recently, CDK2, CCNE1 genes 
were described as cancer prognostic factors [22]. When 
the association is carried out at the function level, there 
are two Uniprot functions (Table S6) representative of 
sustained proliferation hallmark: Mitosis (FDR-adjusted 
p-value 1.7x10-12) and DNA replication (FDR-adjusted 
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Figure 2: Circos plot that summarises the relationships between effectors within pathways and the functions triggered 
by them. Only cancer KEGG pathways (Table 3) related to functions significantly related to survival are represented here. On the right 
side appear the effector circuits grouped according to the pathway they belong to. There is a histogram per pathway that represents the 
proportion of effector pathways upregulated (red), downregulated (blue) and dysregulated in both directions (yellow). On the left side of 
the circo appear the functions triggered by the effector circuits divided into those which are significant when are up-regulated (red), when 
are down-regulated (blue) or when both situations occur (yellow). For each function there is a band that indicates the prognostic of its 
deregulation, which can be good (green) or bad (grey).
Figure 1: Comparison of performances of the different methods for defining pathways and calculating its activity. 
CCAA is compared to DEAP [12], subSPIA [13], using their own software, and topologyGSA [14], DEGraph [6], clipper [5], TAPPA [15], 
PRS [16], PWEA [17], using the implementation available in the topaseq package [18]. The true positive rate has been estimated averaging 
the proportion of significant cancer KEGG pathways (Table 3) across the 12 cancers analyzed and is represented in the Y axis. Vertical 
bars in each point represent 1 SD of the true positive rate for the corresponding method. The false positive rate was estimated from 100 
comparisons of groups (N=25) of identical individuals, randomly sampled from each cancer. The results obtained in the 12 cancers are used 
to obtain a mean value and an error. The X axis represents 1- the false positive rate. Horizontal bars represent in each point represent 1 SD 
of the false positive rate for the corresponding method.
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p-value=5.9x10-8), whose upregulation is significantly 
associated to bad prognostic (See Figures S7A and S7B).
Another cancer hallmark is the activation of 
metastasis and invasion, favored when the Uniprot 
function Cell adhesion decreases. Figure S7C depicts a 
clear association between the downregulation of Cell 
adhesion and the poorer prognostic in patients (FDR-
adjusted p-value=4.4x10-5).
The third classical cancer hallmark in solid tumors 
is the induction of angiogenesis. Angiogenesis appears as 
significantly associated to survival in both Uniprot and 
GO annotations (Tables S6 and S7). Figure S8D depicts 
a significant relationship between the upregulation of 
Positive regulation of angiogenesis and higher patient’s 
mortality (FDR-adjusted p-value=2.9x10-2). Actually, the 
downregulation of the opposite term, Negative regulation 
of angiogenesis, is also associated to bad prognostic, as 
expected, although with marginal significance (FDR-
adjusted p-value=0.055).
Finally, the CCAA method also detects the well-
known Warburg effect, the observed increased uptake and 
utilization of glucose, documented in many human tumor 
types [20, 23]. Our functional analysis clearly predicts 
a bad prognostic for reduced gluconeogenesis (FDR-
adjusted p-value = 8.96x10-6, see Table S6). Actually, it 
has recently been suggested a novel mechanism of cancer 
cell death by increasing the gluconeogenesis pathway 
activity via mTOR inhibitors [24].
In addition, the CCAA method detects several 
terms whose perturbed activity seem a consequence of 
the dedifferentiation process that occur in kidney cancer 
cells, such as the down-activation of Sodium/potassium 
transport (FDR-adjusted p-value=2.95x10-9), Sodium 
transport (FDR-adjusted p-value=8.96x10-6) and, the 
general term Transport (FDR-adjusted p-value= 6.52x10-5) 
(see Table S6).
Moreover, in some specific circuits triggering 
cancer hallmarks the association of the activity of the 
circuit to the mortality of the patient resulted to be 
higher than the individual association of any of the 
genes that form the circuit. Table 5 lists some circuits 
along with the general functional categories clearly 
related to proliferation (DNA replication and Cell 
division), metastasis (Cell adhesion) and Warburg effect 
(Gluconeogenesis and Lipid metabolism). Our results 
show that the initial observation made for the c-Jun 
N-terminal kinase pathway as a superior predictor of 
prognostic in neuroblastoma [2] can be generalized to 
other circuits that trigger cell functionalities related to 
cancer hallmarks.
Cancer progression driven by specific circuits 
instead of specific genes
An additional advantage of using CCAA is 
that the signaling circuits that trigger the functions in 
this particular cancer can be easily traced back. DNA 
replication is an example of function that can easily be 
mapped to the sustained proliferative signaling cancer 
hallmark [20]. The increase in the activity of this function 
is significantly related with poor prognostic (FDR-adjusted 
p-value=5.94x10-8). Three effector circuits belonging to 
the Cell cycle and the p53 pathways (See Figure 3 and 
Table S6) are the ultimate responsible for the activation 
of this function. Moreover, it has been described that 
dysregulation of different genes within the same pathway 
may have a similar impact on downstream pathway 
function [25, 26]. Figure 4 demonstrates how the CCAA 
method can detect the same functional consequence 
(activation of DNA replication) caused by distinct, non-
recurrent, differential gene expression patterns in two 
different cancers (BRCA and KIRC). The detection of the 
specific circuits and the particular gene activities involved 
in the tumorigenesis process has enormous therapeutic 
implications.
DISCUSSION
Models of pathway activity bridge the gap 
between conventional approaches based on single-gene 
biomarkers, or functional enrichment methods, and more 
realistic, model-based approaches. Models use biological 
knowledge available on relevant biological modules (such 
as signaling pathways) to explain how their perturbations 
ultimately cause diseases or responses to treatments. 
Therefore, such perturbations (initially gene expression 
changes) can be related to disease mechanisms or drug 
MoAs [27, 28].
A unique feature of the CCAA method is that, if 
the analysis is made at the level of cell functionality, the 
changes in the activity detected can be traced back to the 
circuits in order to discover which ones are triggering the 
action and what genes are the ultimate causative agents of 
such functional activity changes. Therefore, the resulting 
models can be used to suggest and predict the effect of 
interventions (KOs, drugs or over-expressions) on specific 
genes in the circuits so as to find suitable clinical targets, 
predict side effects, speculate off-target activities, etc. 
Depending on the scenario studied, such interventions can 
be more general or more personalized.
Another relevant feature missing in the rest of 
PAA methods (Table 1) is the possibility of obtaining 
individual values of circuit, effector or function activities 
for each sample. This opens the door to obtaining patient-
specific personalized functional profiles connected to the 
corresponding signaling circuits.
Since clinical data are available at the TCGA 
repository, we were able to find significant associations of 
specific pathway activities to patient survival, proving thus 
the validity of PAA methodology to capture cell processes 
involved in disease outcome.
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Table 5: Circuits which are most significantly associated to survival than their constituent genes
Circuit CircuitStatus
Adjusted
p-value Gene
Gene
Status
Adjusted
p-value
General 
functional 
category
Function
Status
Adjusted
p-value
Cell cycle: CDC45 
MCM7 MCM6 
MCM5 MCM4 
MCM3 MCM2
UP 6.08E-11 CDC7 UP 1.68E-07 DNA replication UP 5.94E-08
Cell cycle: ORC3 
ORC5 ORC4 ORC2 
ORC1 ORC6 
MCM7 MCM6 
MCM5 MCM4 
MCM3 MCM2
UP 1.26E-09 CDC7 UP 1.68E-07 DNA replication UP 5.94E-08
Glucagon signaling 
pathway: G6PC
DOWN 6.57E-06 PPARGC1A DOWN 1.97E-05 Gluconeogenesis DOWN 8.96E-06
Glucagon signaling 
pathway: PCK1
DOWN 4.31E-07 PPARGC1A DOWN 1.97E-05 Gluconeogenesis DOWN 8.96E-06
PPAR signaling 
pathway: PCK1
DOWN 3.75E-05 PCK1 DOWN 6.39E-05 Gluconeogenesis DOWN 8.96E-06
PPAR signaling 
pathway: LPL DOWN 0.00095506 LPL DOWN 0.00509595 Lipid metabolism DOWN 1.59E-05
PPAR signaling 
pathway: CYP7A1
UP 0.00209578 RXRA DOWN 0.00577708 Lipid metabolism DOWN 1.59E-05
Leukocyte 
transendothelial 
migration: CDH5
DOWN 4.81E-05 CDH5 DOWN 6.14E-05 Cell adhesion DOWN 4.46E-05
Adherens junction: 
CTNNA1 CTNNB1 DOWN 3.91E-05 CTNNA1 DOWN 0.00016432 Cell adhesion DOWN 4.46E-05
PPAR signaling 
pathway: CD36
DOWN 5.46E-05 CD36 DOWN 0.00030595 Cell adhesion DOWN 4.46E-05
Proteoglycans in 
cancer: ITGAV*
DOWN 4.81E-05 ITGAV DOWN 0.0006759 Cell adhesion DOWN 4.46E-05
Leukocyte 
transendothelial 
migration: 
PECAM1
DOWN 0.00063309 PECAM1 DOWN 0.0009573 Cell adhesion DOWN 4.46E-05
Adherens junction: 
CDH1*
DOWN 0.00637905 CDH1 DOWN 0.0078199 Cell adhesion DOWN 4.46E-05
AMPK signaling 
pathway: CCNA2 UP 1.04E-12 STRADA UP 1.34E-07 Cell division DOWN 0.00152171
Tight junction: 
PARD6A MPP5
DOWN 1.45E-05 CDC42 DOWN 0.00011452 Cell division DOWN 0.00152171
The circuits are defined as the pathway to which it belongs to and the final effector node that triggers the function. The 
status for circuits, genes and functions are UP or DOWN depending on the respective increase or decrease of their activities 
when the cancer is compared to the normal tissue. The gene column contains the gene with the best association to survival 
(lower adjusted p-value) among all the genes in the corresponding circuit.
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Figure 4: DNA replication is triggered by the same circuits in KIRC and BRCA, but using a different pattern of gene 
activation. The Hipathia program (http://hipathia.babelomics.org) detected a total of four effector circuits in two pathways, Cell Cycle and 
P53 signaling, that are used by both cancers to trigger DNA replication. Arrows in red represent activated circuits. Genes in red represent 
genes upregulated in the cancer with respect to the corresponding normal tissue; genes in blue represent downregulated genes and genes 
with no color were not differentially expressed. Squares at the end of the circuit represent the cell functions triggered by the circuits. A. Cell 
Cycle signaling pathway in KIRC with three effector circuits activated (highlighted), one of them ending in the node containing proteins 
CDC6, ORC3, ORC5, ORC4, ORC2, ORC1 and ORC6, the second one ending in node with proteins CDC45, MCM7, MCM6, MCM5, 
MCM4, MCM3 and MCM2 and the last one ending in node with proteins ORC3, ORC5, ORC4, ORC2, ORC1, ORC6, MCM7, MCM6, 
MCM5, MCM4, MCM3 and MCM2. B. P53 signaling pathway in BRCA with the effector circuit ending in protein RRM2B highlighted. C. 
Cell Cycle pathway in BRCA with the same effector circuits activated that in KIRC, but using a different set of gene activations. D. P53 
signaling pathway in BRCA with the same effector circuit activated that in KIRC, but using a different set of gene activations.
Figure 3: Increase of DNA replication activity is related to bad prognostic. Effector nodes in two pathways trigger DNA 
replication in KIRC, as detected by the Hipathia program (http://hipathia.babelomics.org). Genes in red represent genes upregulated in 
the cancer with respect to the corresponding normal tissue; genes in blue represent downregulated genes and genes with no color were not 
differentially expressed. A. Cell Cycle signaling pathway with three effector circuits highlighted, one of them ending in the node containing 
proteins CDC6, ORC3, ORC5, ORC4, ORC2, ORC1 and ORC6, the second one ending in node with proteins CDC45, MCM7, MCM6, 
MCM5, MCM4, MCM3 and MCM2 and the last one ending in node with proteins ORC3, ORC5, ORC4, ORC2, ORC1, ORC6, MCM7, 
MCM6, MCM5, MCM4, MCM3 and MCM2. B. p53 signaling pathway with the effector circuit ending in protein RRM2B highlighted. C. 
Survival Kaplan-Meier (K-M) curves obtained for Uniprot function DNA replication.
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Finally, it is worth mentioning that the integration 
of information on protein functionality in the model, 
if it is available, is straightforward. (See Methods for 
details). Other omic data (methylomics data, Copy 
Number Variation, etc.) could also be easily introduced 
in the model providing they could be coded as proxies of 
presence and/or integrity of the protein.
MATERIALS AND METHODS
Data source and processing
We used 12 cancer types from The Cancer 
Genome Atlas (TCGA) data portal (https://tcga-data.
nci.nih.gov/tcga/) in which RNA-seq counts for 
healthy control samples were available in addition to 
the cancer samples: Bladder Urothelial Carcinoma 
(BLCA) [29], Breast invasive carcinoma (BRCA) [30], 
Colon adenocarcinoma (COAD) [31], Head and Neck 
squamous cell carcinoma (HNSC) [32], Kidney renal 
clear cell carcinoma (KIRC) [19], Kidney renal papillary 
cell carcinoma (KIRP) [33], Liver hepatocellular 
carcinoma (LIHC), Lung adenocarcinoma (LUAD) [34], 
Lung squamous cell carcinoma (LUSC) [35], Prostate 
adenocarcinoma (PRAD) [36], Thyroid carcinoma 
(THCA) [37] and Uterine Corpus Endometrial 
Carcinoma (UCEC) [38] (Table 2).
Since TCGA cancer data has different origins 
and underwent different management processes, non-
biological experimental variations (batch effect) associated 
to Genome Characterization Center (GCC) and plate ID 
must be removed from the RNA-seq data. The COMBAT 
method [10] was used for this purpose. This method 
estimates the location and scale model parameters that 
represent batch effects and shrink them towards the overall 
mean of the batch effect estimates. Then, these estimates 
are used to adjust the data for batch effects. Then, we 
applied the trimmed mean of M-values normalization 
method (TMM) method [11] for data normalization. 
TMM is a very efficient normalization method that 
corrects a well-known artifact derived from the RNA-Seq 
technology: the RNA-composition bias. When comparing 
two different samples, the number of read counts of an 
equally expressed gene may vary depending on the level 
of expression of the other genes due to the fact that the 
library depth is fixed. The read counts of a gene represent 
the proportion of the gene with respect to the total RNA 
production of the sample, but this proportion is not a 
quantitative number which can be compared if the total 
RNA production is different between samples. TMM 
normalization estimates the ratio of RNA production 
between samples with a weighted trimmed mean of the log 
expression ratios (trimmed mean of M values or TMM). 
Then it uses this estimation to modify the observed library 
size of a sample to a comparable library size which 
follows the proportion of RNA production between the 
samples. The resulting normalized values were entered to 
the pathway activity analysis method.
Modelling framework
Modelling of pathway activity requires initially of 
a formal description of the relationships between proteins 
within the pathway, which can be taken from different 
pathway repositories. Here KEGG pathways [39] are 
used, but any other repository could be used instead, 
as Reactome [40] or others. It also requires of a way to 
estimate the activation status of each protein, which 
accounts for the intensity of signal they can transmit along 
the pathway.
A total of 60 KEGG pathways (see Table 6), 
which include the main KEGG categories related 
to signaling, such as: signal transduction pathways, 
Signaling molecules and interaction pathways, Cell 
growth and death, Cell Communication, endocrine 
system and immune system, as well as some other 
related pathways are used in this modelling framework. 
This selection of pathways includes a total of 2212 
gene products that participate in 3379 nodes. It must 
be noted that any gene product can participate in more 
than one node (even in different pathways) and a node 
can contain more than one gene product. Pathways are 
directed networks in which nodes (composed by one or 
more proteins) relate to each other by edges. Only two 
different kinds of relation between nodes are considered: 
activations and inhibitions. In KEGG pathways, edges 
define different types of protein interactions that include 
phosphorilations, ubiquitinations, glycosilations, 
etc., but they include a label indicating if they act as 
activations or inhibitions.
In order to transmit the signal along the pathway, 
a protein needs: first, to be present and functional, and 
second, to be activated by other protein. Preferably, 
the activity of the proteins should be inferred from 
(phospho) proteomic and chemoproteomic experiments 
[41], however, the production of these types of data still 
results relatively complex [42]. Instead, an extensively 
used approach is taking the presence of the mRNA 
corresponding to the protein as a proxy for the presence 
of the protein [5-8, 42, 43]. Therefore, the presence of 
the mRNAs corresponding to the proteins present in the 
pathway is quantified as a normalized value between 
0 and 1. Second, a value of signal intensity transmitted 
through a protein is computed, taking into account the 
level of expression of the corresponding mRNA and the 
intensity of the signal arriving to it. The net value of signal 
transmitted across the pathway corresponds to the signal 
values transmitted by the last proteins of the pathway 
that ultimately trigger the cell functions activated by the 
pathway.
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Table 6: KEGG pathways modeled in this study
KEGG identifier Name
hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04010 MAPK signaling pathway
hsa04012 ErbB signaling pathway
hsa04310 Wnt signaling pathway
hsa04330 Notch signaling pathway
hsa04340 Hedgehog signaling pathway
hsa04350 TGF-beta signaling pathway
hsa04390 Hippo signaling pathway
hsa04370 VEGF signaling pathway
hsa04630 Jak-STAT signaling pathway
hsa04064 NF-kappa B signaling pathway
hsa04668 TNF signaling pathway
hsa04066 HIF-1 signaling pathway
hsa04068 FoxO signaling pathway
hsa04020 Calcium signaling pathway
hsa04071 Sphingolipid signaling pathway
hsa04024 cAMP signaling pathway
hsa04022 cGMP-PKG signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04152 AMPK signaling pathway
hsa04150 mTOR signaling pathway
hsa04110 Cell cycle
hsa04114 Oocyte meiosis
hsa04210 Apoptosis
hsa04115 p53 signaling pathway
hsa04510 Focal adhesion
hsa04520 Adherens junction
hsa04530 Tight junction
hsa04540 Gap junction
hsa04611 Platelet activation
hsa04620 Toll-like receptor signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04622 RIG-I-like receptor signaling pathway
hsa04650 Natural killer cell mediated cytotoxicity
hsa04660 T cell receptor signaling pathway
hsa04662 B cell receptor signaling pathway
hsa04664 Fc epsilon RI signaling pathway
hsa04666 Fc gamma R-mediated phagocytosis
hsa04670 Leukocyte transendothelial migration
hsa04062 Chemokine signaling pathway
hsa04910 Insulin signaling pathway
hsa04922 Glucagon signaling pathway
hsa04920 Adipocytokine signaling pathway
hsa03320 PPAR signaling pathway
hsa04912 GnRH signaling pathway
 (Continued )
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Decomposing pathways into circuits
Pathways are represented by directed graphs, 
which connect input (receptor) nodes to output (effector) 
nodes. The signal arrives to an initial input node and is 
transmitted along the pathway following the direction of 
the interactions until it reaches an output node that triggers 
an action within the cell. Thus, from different input nodes 
the signal may follow different routes along the pathway 
to reach different output nodes. Within this modelling 
context, a canonical circuit is defined as any possible route 
the signal can traverse to be transmitted from a particular 
input to a specific output node (see Figure 5, left).
Output nodes at the end of canonical are the ultimate 
responsible to carry out the action the signal is intended to 
trigger in the cell. Then, from a functional viewpoint, an 
effector circuit can be defined as a higher-level signaling 
entity composed by the collection of all the canonical 
circuits ending in an unique output (effector) node (see 
Figure 5, center). When applied to effector circuits, the 
method returns the joint intensity of the signal arriving to 
the corresponding effector node.
A total of 6101 canonical circuits and 1038 effector 
circuits can be defined in the 60 pathways modelled.
Computing the circuit activity
The methodology proposed uses gene expression 
values as proxies of protein presence values, and 
consequently of potential protein activation values 
[5-8, 42-44]. The inferred protein activity values are 
then transformed into node activity values using the 
information on node composition taken from KEGG. 
KEGG defines two types of nodes: plain nodes, which 
may contain one or more proteins, whose value is 
summarized as the percentile 90 of the values of the 
proteins contained in it, and complex nodes, for which 
the minimum value of the proteins contained (the 
limiting component of the complex), is taken as the node 
activity value.
Once the node activity values have been estimated, 
the computation of the signal intensity across the different 
circuits of the pathways is performed by means of an 
iterative algorithm beginning in the input nodes of each 
circuit. In order to initialize the circuit signal we assume 
an incoming signal value of 1 in the input nodes of any 
circuit. Then, for each node n of the network, the signal 
value is propagated along the nodes according to the 
following recursive rule:
S s s1 1 1n n
s A
a
s I
i
a i
∏ ∏υ ( ) ( )= − − −
 
(1)
Where Sn is the signal intensity for the current node 
n, vn is its normalized value, A is the total number of 
activation signals (sa), arriving to the current node from 
activation edges, I is the total number of inhibitory signals 
(si) arriving to the node from inhibition edges.
The algorithm to compute the transmission of the 
signal along the network is a recursive method based on 
the Dijkstra algorithm [45]. Each time the signal value 
across a node is updated in a recursion and the difference 
with the previous value is greater than a threshold, all the 
nodes to which an edge arrives from the current updated 
node are marked to be updated. The recursion continues 
until the update in the values is below the threshold. The 
advantage if using an iterative method is that the signal 
becomes steady even in cases of loops in the pathway 
topology, allowing a more precise estimation of circuit 
activities. Many PAA methods simply cannot handle with 
loops and artificially disconnect them or even remove 
them from the calculations [5, 6, 8, 13-15, 17]. Figure 
6 represents the computation of the intensity of signal 
transmission across a node, and exemplifies in a simple 
scenario how the signal is transmitted across a circuit.
KEGG identifier Name
hsa04915 Estrogen signaling pathway
hsa04914 Progesterone-mediated oocyte maturation
hsa04921 Oxytocin signaling pathway
hsa04919 Thyroid hormone signaling pathway
hsa04916 Melanogenesis
hsa04261 Adrenergic signaling in cardiomyocytes
hsa04270 Vascular smooth muscle contraction
hsa04722 Neurotrophin signaling pathway
hsa05200 Pathways in cancer
hsa05231 Choline metabolism in cancer
hsa05202 Transcriptional misregulation in cancer
hsa05205 Proteoglycans in cancer
hsa04971 Gastric acid secretion
hsa05160 Hepatitis C
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Figure 5: Schema that illustrates the relationship between circuits, effector circuits and functions. Left: signaling circuits, 
which are canonical sub-pathways that transmit signals from a unique receptor to a unique effector node. Center: effector circuits that 
represent the combined activity of all the signals that converge into a unique effector node. Right: functional activity that represents the 
combined effect of the signal received by all the effectors that trigger a particular cell function.
Figure 6: Schematic representation of the signal propagation algorithm used. Upper part: the three types of activity 
transmitted: left) the combination of two activations, center) the combination of an activation and an inhibition and right) the combination 
of two inhibitions. Central part: the normalized values of gene expression are assigned to the corresponding nodes in the circuits. Lower 
part: the signal starts with a value of 1 in the receptor node A and is propagated by multiplying the weights assigned to each node in the 
central part following the rules depicted in the upper part.
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Effector circuits and functional analysis
Effector nodes at the end of the circuits trigger 
specific functions in the cell. These functions are defined 
here based on the annotations of the proteins contained 
in the effector node. Gene Ontology [46] (GO) terms 
corresponding to the biological process ontology 
(February 16, 2016 release) and molecular function 
keywords of Uniprot [47] (release of September 21, 2015) 
are used.
The signal intensity received by the effector node 
can be propagated to the functions triggered by them 
following the same rationale of signal propagation along 
the circuits. Figure 5 illustrates how effector circuits 
are composed by different canonical circuits and how 
functions can be triggered by several effector circuits.
Straightforward integration of transcriptomic 
and genomic data
Finally, the integration of genomic and 
transcriptomic data in the proposed modeling framework 
of signaling pathways is straightforward. In order to 
transmit the signal a protein needs to be present (gene 
expressed) and to be functional (harboring no impairing 
mutations). Genomic data can be integrated with 
transcriptomic data to infer combined gene activity and 
integrity (and consequently potential functionality). In 
the simplest approach [9] the normalized expression 
value of genes harboring mutations is multiplied by 0 if 
the pathogenicity (e.g. SIFT [48], PolyPhen [49]) and 
conservation indexes (e.g. phastCons [50]) are beyond a 
given threshold (taking into account the inheritance mode), 
or if the consequence type of the mutation (stop gain, stop 
loss, and splicing disrupting) is deleterious per se, because 
it is considered to produce a non-functional protein. The 
HiPathia program enables the analysis of mutations 
found in standard variant files (VCF) from whole exome/
genome sequencing experiments in combination with gene 
expression values.
Specificity of the method of canonical circuit 
activity analysis (CCAA)
To estimate the false positive rate, different groups 
of N identical individuals were generated and further 
divided into two datasets that were compared to each 
other for finding differentially activated circuits. This 
comparison was repeated 2000 times for different data 
sizes (N = 20, 50, 100, 200 and 400 individuals) in three 
different scenarios: i) N individuals were randomly 
sampled among KIRC patients; ii) For each gene g, an 
empirical distribution of gene expression values was 
derived from the patients of the KIRC dataset. Specifically, 
the mean μg and variance σ
2
g was inferred for each gene g 
taking into account the gene expression values measured 
for these gene in all the samples. Then, N individuals were 
generated by simulating the gene expression values for 
each gene g as random numbers sampled from a normal 
distribution N(μg,σ
2
g); iii) N individuals were generated 
by simulating their gene expression values as random 
numbers from a normal distribution N(0.5, 0.05) as above.
Since the individuals involved in the comparison 
were taken either from the same type of samples or were 
generated in the same way, any differential activation 
found can be considered a false positive. The comparisons 
were carried out for both, circuits and effector proteins.
Sensitivity of the Canonical Circuit Activity 
Analysis (CCAA) method
To estimate the true positive rate, we tested a 
scenario in which biological differences are expected. 
For this purpose, we used the two 2 cancers in Table 2 
with more individuals, BRCA [30] and KIRC [19]. For 
each of the two cancers we generated 100 datasets of 
N=50,100,200 and 400 samples by sampling randomly 
both the normal and tumor samples in such a way that 
the normal/tumor proportion remained the same as in 
the original dataset (Table 2). Specifically, for BRCA 
(with 113 normal tissue and 1057 tumor), N= 50, 100, 
200 and 400 correspond to normal/tumor proportions of 
5/45, 10/90, 19/181 and 39/361, respectively. In the case 
of KIRC (with 68 normal and 470 tumor) the respective 
proportions were 6/44, 13/87, 25/175 and 51/349. In 
total, we generated 2x100x4 = 800 datasets. CCAA was 
calculated at the level of signaling circuits and effector 
circuits for both datasets. The true positive rate was 
estimated as the number of cancer pathways containing 
one or more differentially activated circuits divided by the 
total number of cancer pathways. Although a gold standard 
is always difficult in this type of scenario, we can expect 
changes in the 14 cancer pathways, as defined in KEGG 
(Cancer pathways category, see Table 3). Additionally, 
we produced an extended table of 49 cancer pathways 
curated by expert collaborators from the Valencia Institute 
of Oncology (IVO) (Table 4).
Comparison with other available methods for 
defining and scoring pathway activity
We compared the reliability of the CCAA method 
proposed here to other proposals for defining sub-
pathways and for calculating an activity score for them. 
Among the methods listed in Table 1 only nine could be 
applied to RNA-seq data and have software available for 
running them. These are: DEAP [12], subSPIA [13], using 
their own software, and topologyGSA [14], DEGraph 
[6], clipper [5], TAPPA [15], PRS [16], PWEA [17], 
implemented in the topaseq package [18]. The relative 
performance of the methods compared was derived from 
the estimation of their ratios of false positives and false 
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negatives in a similar way than above. In order to estimate 
the false positives rate 12 cancer datasets (Table 2) were 
used. For each cancer, 50 patients were randomly sampled 
100 times. Any sampled set is divided into two equally 
sized subsets that are subsequently compared. Then, the 
100 values obtained for each cancer are used to determine 
a mean value and a SD for the false positives ratio. The 
same 12 cancers (Table 2) were used to estimate the 
true positive rates. For each cancer versus normal tissue 
comparison the number of significant cancer pathways 
was calculated and divided by the total number of cancer 
pathways. The ratios were calculated for both the 14 
cancer pathways as defined in KEGG (Cancer pathways 
category, see Table 3) and the extended list of 49 curated 
cancer pathways (Table 4).
Survival in cancer
The KIRC TCGA samples contain survival 
information among the clinical data available. These can 
be used to check whether the circuit or function activities 
estimated for each patient have a relationship with survival 
or not. Kaplan-Meier (K-M) curves [51] were estimated 
using the function survdiff from the survival R package 
(https://cran.r-project.org/web/packages/survival/) for 
each signaling circuit, each effector circuit and each 
cell function (either Uniprot or GO definitions) with 
a significant difference of activity when cancers were 
compared to the corresponding controls. Specifically, 
the 10% of individuals presenting the highest (or lowest) 
activity were compared to the rest of them.
Availability of data and materials
A user-friendly web server that runs the code for 
carrying out the CCAA method is freely available at http://
hipathia.babelomics.org.
The R code implementing the method is available at 
https://github.com/babelomics/hipathia.
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